Official reprint from UpToDate®
www.uptodate.com ©2015 UpToDate®

Oral lesions

Beth G Goldstein, MD
Adam O Goldstein, MD, MPH
Section Editors
Robert P Dellavalle, MD, PhD, MSPH
Daniel G Deschler, MD, FACS
Deputy Editor
Rosamaria Corona, MD, DSc


Diagnosing and treating dermatologic lesions of the mouth and gums is challenging for most clinicians because of the wide variety of disease processes that can present with similar appearing lesions and the fact that most clinicians receive inadequate training in mouth diseases. In a study of oral lesions in older adult patients, for example, almost all clinicians surveyed felt that it was important to examine older patients' mouths, but less than one-fifth stated that they routinely performed such examinations [1]. Almost four-fifths did not correctly diagnose a clinical picture of an early squamous cell carcinoma.

One of the keys to improving accuracy in diagnosing oral lesions is forming an appropriate differential diagnosis. This review will discuss the presentation and treatment of the most common oral lesions, including tumors, infections, autoimmune and connective tissues diseases, aphthous ulcers, and other miscellaneous oral lesions.

Gingivitis, periodontal disease, odontogenic infections, and halitosis are discussed separately. (See "Gingivitis and periodontitis in adults: Classification and dental treatment" and "Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections" and "Bad breath".)


Squamous cell carcinoma — Cancer of the oral cavity is associated with ulcers or masses that do not heal and with dental changes or poorly fitting dentures. Tongue and lip cancers present as exophytic or ulcerative lesions often associated with pain. Up to two-thirds of patients with primary tongue lesions have nodal disease; the incidence is substantially lower in patients with hard palate and lip cancers. (See "Overview of treatment for head and neck cancer" and "Overview of the diagnosis and staging of head and neck cancer".)

Persistent papules, plaques, erosions, or ulcers in the mouth should be biopsied to rule out squamous cell carcinoma, particularly in patients with appropriate risk factors (picture 1A-C). It has been estimated that the use of tobacco and alcohol account for up to 80 percent of cases of squamous cell carcinoma of the head and neck [1]. The combined effect of alcohol and smoking is multiplicative with the risk of developing head and neck cancer being as much as 200 times greater for heavy smokers and drinkers. A subset of oropharyngeal squamous cell carcinoma is associated with human papillomavirus (HPV) infection, particularly with high-risk type 16 (HPV-16). Oral infection with HPV-16 confers an approximately 50-fold increase in risk for HPV-positive oropharyngeal squamous cell carcinoma [2]. (See "Epidemiology and risk factors for head and neck cancer" and "Human papillomavirus associated head and neck cancer".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2015. | This topic last updated: Apr 9, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
  1. Morgan R, Tsang J, Harrington N, Fook L. Survey of hospital doctors' attitudes and knowledge of oral conditions in older patients. Postgrad Med J 2001; 77:392.
  2. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693.
  3. Cianfriglia F, Di Gregorio DA, Cianfriglia C, et al. Incidence of human papillomavirus infection in oral leukoplakia. Indications for a viral aetiology. J Exp Clin Cancer Res 2006; 25:21.
  4. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6:1702.
  5. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer 2000; 82:1871.
  6. van der Waal I, Schepman KP, van der Meij EH. A modified classification and staging system for oral leukoplakia. Oral Oncol 2000; 36:264.
  7. Grady D, Greene J, Daniels TE, et al. Oral mucosal lesions found in smokeless tobacco users. J Am Dent Assoc 1990; 121:117.
  8. Gillenwater AM, Vigneswaran N, Fatani H, et al. Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity! Adv Anat Pathol 2013; 20:416.
  9. Bagan J, Scully C, Jimenez Y, Martorell M. Proliferative verrucous leukoplakia: a concise update. Oral Dis 2010; 16:328.
  10. Pentenero M, Meleti M, Vescovi P, Gandolfo S. Oral proliferative verrucous leucoplakia: are there particular features for such an ambiguous entity? A systematic review. Br J Dermatol 2014; 170:1039.
  11. Issrani R, Prabhu N, Keluskar V. Oral proliferative verrucous leukoplakia: A case report with an update. Contemp Clin Dent 2013; 4:258.
  12. Schoelch ML, Sekandari N, Regezi JA, Silverman S Jr. Laser management of oral leukoplakias: a follow-up study of 70 patients. Laryngoscope 1999; 109:949.
  13. Poveda-Roda R, Bagan JV, Jiménez-Soriano Y, et al. Retinoids and proliferative verrucous leukoplakia (PVL). A preliminary study. Med Oral Patol Oral Cir Bucal 2010; 15:e3.
  14. Silverman S Jr, Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:154.
  15. DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998; 5:733.
  16. Eisen D, Voorhees JJ. Oral melanoma and other pigmented lesions of the oral cavity. J Am Acad Dermatol 1991; 24:527.
  17. Kaugars GE, Heise AP, Riley WT, et al. Oral melanotic macules. A review of 353 cases. Oral Surg Oral Med Oral Pathol 1993; 76:59.
  18. Vaughan V, Ferringer T. Granular cell tumor. Cutis 2014; 94:275, 279.
  19. Owens BM, Johnson WW, Schuman NJ. Oral amalgam pigmentations (tattoos): a retrospective study. Quintessence Int 1992; 23:805.
  20. Chi AC, Lambert PR 3rd, Richardson MS, Neville BW. Oral mucoceles: a clinicopathologic review of 1,824 cases, including unusual variants. J Oral Maxillofac Surg 2011; 69:1086.
  21. Böhler-Sommeregger K, Kutschera-Hienert G. Cryosurgical management of myxoid cysts. J Dermatol Surg Oncol 1988; 14:1405.
  22. Huang IY, Chen CM, Kao YH, Worthington P. Treatment of mucocele of the lower lip with carbon dioxide laser. J Oral Maxillofac Surg 2007; 65:855.
  23. Ladizinski B, Lee KC. A nodular protuberance on the hard palate. JAMA 2014; 311:1558.
  24. Loukas M, Hulsberg P, Tubbs RS, et al. The tori of the mouth and ear: a review. Clin Anat 2013; 26:953.
  25. García-García AS, Martínez-González JM, Gómez-Font R, et al. Current status of the torus palatinus and torus mandibularis. Med Oral Patol Oral Cir Bucal 2010; 15:e353.
  26. Budtz-Jørgensen E. Oral mucosal lesions associated with the wearing of removable dentures. J Oral Pathol 1981; 10:65.
  27. Kanli A, Demirel F, Sezgin Y. Oral candidosis, denture cleanliness and hygiene habits in an elderly population. Aging Clin Exp Res 2005; 17:502.
  28. Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986; 314:686.
  29. Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976; 41:498.
  30. Hebert AA, Lopez MD. Oral lesions in pediatric patients. Adv Dermatol 1997; 12:169.
  31. Amir J, Harel L, Smetana Z, Varsano I. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol 1999; 16:259.
  32. Spruance SL, Crumpacker CS, Schnipper LE, et al. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob Agents Chemother 1984; 25:553.
  33. Raborn GW, Martel AY, Grace MG, McGaw WT. Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85:55.
  34. Bieber T, Chosidow O, Bodsworth N, et al. Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol 2014; 13:791.
  35. Lapins J, Gaines H, Lindbäck S, et al. Skin and mucosal characteristics of symptomatic primary HIV-1 infection. AIDS Patient Care STDS 1997; 11:67.
  36. Sarti GM, Haddy RI, Schaffer D, Kihm J. Black hairy tongue. Am Fam Physician 1990; 41:1751.
  37. Lima Gda S, Silva GF, Gomes AP, et al. Diclofenac in hyaluronic acid gel: an alternative treatment for actinic cheilitis. J Appl Oral Sci 2010; 18:533.
  38. Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, et al. The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico. Medicine (Baltimore) 2003; 82:39.
  39. Nichols CM, Flaitz CM, Hicks MJ. Treating Kaposi's lesions in the HIV-infected patient. J Am Dent Assoc 1993; 124:78.
  40. Reichart PA. Oral ulcerations in HIV infection. Oral Dis 1997; 3 Suppl 1:S180.
  41. Alegre M, Dalmau J, Domingo P, et al. Successful treatment of major oral aphthous ulcers in HIV-1 infection after highly active antiretroviral therapy. Int J Infect Dis 2007; 11:278.
  42. Kuteyi T, Okwundu CI. Topical treatments for HIV-related oral ulcers. Cochrane Database Syst Rev 2012; 1:CD007975.
  43. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487.
  44. Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis 1999; 28:892.
  45. Ship JA. Recurrent aphthous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81:141.
  46. Savage NW, Mahanonda R, Seymour GJ, et al. The proportion of suppressor-inducer T-lymphocytes is reduced in recurrent aphthous stomatitis. J Oral Pathol 1988; 17:293.
  47. Landesberg R, Fallon M, Insel R. Alterations of T helper/inducer and T suppressor/inducer cells in patients with recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol 1990; 69:205.
  48. McBride DR. Management of aphthous ulcers. Am Fam Physician 2000; 62:149.
  49. Rogers RS 3rd. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg 1997; 16:278.
  50. Lalla RV, Choquette LE, Feinn RS, et al. Multivitamin therapy for recurrent aphthous stomatitis: a randomized, double-masked, placebo-controlled trial. J Am Dent Assoc 2012; 143:370.
  51. Shim YJ, Choi JH, Ahn HJ, Kwon JS. Effect of sodium lauryl sulfate on recurrent aphthous stomatitis: a randomized controlled clinical trial. Oral Dis 2012; 18:655.
  52. Liu C, Zhou Z, Liu G, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med 2012; 125:292.
  53. Soylu Özler G. Silver nitrate cauterization: a treatment option for aphthous stomatitis. J Craniomaxillofac Surg 2014; 42:e281.
  54. Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005; 153:521.
  55. Rhodus NL, Bereuter J. An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis: a pilot study. Quintessence Int 1998; 29:769.
  56. Ruah CB, Stram JR, Chasin WD. Treatment of severe recurrent aphthous stomatitis with colchicine. Arch Otolaryngol Head Neck Surg 1988; 114:671.
  57. Thornhill MH, Baccaglini L, Theaker E, Pemberton MN. A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 2007; 143:463.
  58. Lynde CB, Bruce AJ, Rogers RS 3rd. Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 2009; 145:273.
  59. Altenburg A, Abdel-Naser MB, Seeber H, et al. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007; 21:1019.
  60. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126:923.
  61. Bonnetblanc JM, Royer C, Bedane C. Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology 1996; 193:321.
  62. Hello M, Barbarot S, Bastuji-Garin S, et al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. Medicine (Baltimore) 2010; 89:176.
  63. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335:1078.
  64. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341:1284.
  65. Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999; 38:917.
  66. Lourenço SV, de Carvalho FR, Boggio P, et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of the inflammatory infiltrate. J Cutan Pathol 2007; 34:558.
  67. Ranginwala AM, Chalishazar MM, Panja P, et al. Oral discoid lupus erythematosus: A study of twenty-one cases. J Oral Maxillofac Pathol 2012; 16:368.
  68. Callen JP. Oral manifestations of collagen vascular disease. Semin Cutan Med Surg 1997; 16:323.
  69. Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin 2011; 29:419.
  70. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9:29.
  71. Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006; 39:617.
  72. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.
  73. Kohorst JJ, Bruce AJ, Torgerson RR, et al. A population-based study of the incidence of burning mouth syndrome. Mayo Clin Proc 2014; 89:1545.
  74. Sun A, Wu KM, Wang YP, et al. Burning mouth syndrome: a review and update. J Oral Pathol Med 2013; 42:649.
  75. Olitsky SE. Picture of the month. Telangiectases secondary to hereditary hemorrhagic telangiectasia. Arch Pediatr Adolesc Med 2011; 165:275.
  76. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24:203.
  77. Reamy BV, Derby R, Bunt CW. Common tongue conditions in primary care. Am Fam Physician 2010; 81:627.
  78. Pastore L, Carroccio A, Compilato D, et al. Oral manifestations of celiac disease. J Clin Gastroenterol 2008; 42:224.
  79. Bøhmer T, Mowé M. The association between atrophic glossitis and protein-calorie malnutrition in old age. Age Ageing 2000; 29:47.
  80. Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol 2007; 24:317.
  81. Rose AE, Leger M, Chu J, Meehan S. Cheilitis granulomatosa. Dermatol Online J 2011; 17:15.
  82. Jover-Diaz F, Cuadrado-Pastor JM, Talents-Bolos A, Martin-Gonzalez C. Black tongue associated with linezolid. Am J Ther 2010; 17:e115.
  83. Guinovart RM, Carrascosa JM, Bielsa I, et al. A black tongue in a young woman. Clin Exp Dermatol 2011; 36:429.
  84. Cohen PR. Black tongue secondary to bismuth subsalicylate: case report and review of exogenous causes of macular lingual pigmentation. J Drugs Dermatol 2009; 8:1132.
  85. Ma DL, Vano-Galvan S. Hyperpigmentation in Laugier-Hunziker syndrome. CMAJ 2011; 183:1402.
  86. Holzwanger JM, Rudolph RI, Heaton CL. Pigmented fungiform papillae of the tongue: a common variant of oral pigmentation. Int J Dermatol 1974; 13:403.
  87. Romiti R, Molina De Medeiros L. Pigmented fungiform papillae of the tongue. Pediatr Dermatol 2010; 27:398.
  88. Werchniak AE, Storm CA, Dinulos JG. Hyperpigmented patches on the tongue of a young girl. Pigmented fungiform papillae of the tongue. Arch Dermatol 2004; 140:1275.
  89. Al-Fagaan F, Joseph B. A case of pigmented fungiform papillae of the tongue in a Middle Eastern woman. Med Princ Pract 2014; 23:167.
  90. Assimakopoulos D, Patrikakos G, Fotika C, Elisaf M. Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med 2002; 113:751.
  91. Sigal MJ, Mock D. Symptomatic benign migratory glossitis: report of two cases and literature review. Pediatr Dent 1992; 14:392.
  92. Brooks JK, Balciunas BA. Geographic stomatitis: review of the literature and report of five cases. J Am Dent Assoc 1987; 115:421.
  93. Ishibashi M, Tojo G, Watanabe M, et al. Geographic tongue treated with topical tacrolimus. J Dermatol Case Rep 2010; 4:57.
  94. Tosti A, Piraccini BM, Peluso AM. Contact and irritant stomatitis. Semin Cutan Med Surg 1997; 16:314.
  95. Lazarchik DA, Filler SJ. Effects of gastroesophageal reflux on the oral cavity. Am J Med 1997; 103:107S.
Topic Outline